November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
April 2018 in “Journal of Investigative Dermatology” CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
June 2024 in “International Journal of Dermatology” Topical metformin 10% cream may help treat central centrifugal cicatricial alopecia.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
October 2025 in “Electronic Theses and Dissertations Repository (University of Pisa)” Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
10 citations
,
April 2020 in “Dermatology and therapy” Calcipotriol works almost as well as clobetasol for mild to moderate alopecia areata with fewer side effects.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
5 citations
,
January 2014 in “Asian Journal of Chemistry” Researchers developed a quick and reliable method to test for betamethasone dipropionate and calcipotriol in ointments and drugs.
9 citations
,
November 1980 in “Geburtshilfe und Frauenheilkunde” Fenoterol treatment causes increased hair growth due to higher metabolism in hair follicles, not hormones.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
97 citations
,
January 2020 in “Advances in chronic kidney disease” Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.
March 2025 in “Buletin Veteriner Udayana” The cat's mite and lice infestations were successfully treated with medication and supportive care.
23 citations
,
August 1987 in “PubMed” The ferret had hyperadrenocorticism and other health issues like heart, liver, and kidney problems.
20 citations
,
August 2023 in “Saudi Pharmaceutical Journal” Niosomes can effectively deliver cetirizine topically for treating alopecia.
September 2010 in “Reactions weekly” The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
January 2016 in “Huanjing yu Jiankang Zazhi” 65 citations
,
April 2000 in “The Laryngoscope” Clotrimazole, miconazole, and tolnaftate are likely safe, but gentian violet is risky.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
6 citations
,
December 2015 in “Medicine” Cronkhite-Canada syndrome may be more treatable and less severe than previously thought.